Advertisement

Levetiracetam

  • P. N. Patsalos
Chapter

Abstract

Levetiracetam (Fig. 1) corresponds chemically to (S)-alpha-ethyl-2 oxo-1-pyrrolidine acetamide with an empirical formula of C8H14N2O2 and a molecular weight of 170.21.

Keywords

Valproic Acid Therapeutic Drug Monitoring Plasma Clearance Pharmacokinetic Interaction Epoxide Hydrolase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Freitas-Lima P, Alexandre V, Pereira LRL, Feletti F, Perucca E, Sakamoto AC. Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. Epilepsy Res. 2011;94:117–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 2002;48:217–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Falcao A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response relationships of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis. CNS Drugs. 2012;26:79–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CB, Shields WD. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43:518–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Sullivan T. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443–53.PubMedCrossRefGoogle Scholar
  7. 7.
    May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit. 2003;25:690–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother. 2004;13:1–168.Google Scholar
  10. 10.
    Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia. 2003;44:171–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations